Literature DB >> 2216191

Ovarian metastases are rare in stage I adenocarcinoma of the cervix.

J V Brown1, Y S Fu, J S Berek.   

Abstract

Over a 32-year period at the University of California, Los Angeles Medical Center, all cases of adenocarcinoma and adenosquamous carcinoma of the uterine cervix were reviewed to determine the incidence of ovarian metastases in stage I disease. One of 25 patients (4.0%) who underwent an exploratory laparotomy and radical hysterectomy had a microscopic ovarian metastasis. A literature review identified nine additional patients who had ovarian metastases and stage I adenocarcinoma of the cervix. Including our series, the overall reported rate of ovarian metastases is 1.8%. All ten patients had at least one of the following additional characteristics: They were postmenopausal, they had adnexal pathology, or they had positive pelvic lymph nodes. Thus, ovarian preservation is warranted in premenopausal patients who do not have ovarian pathology or evidence of other metastatic disease at surgery. Bilateral oophorectomy may be performed if frozen-section examination of enlarged or suspicious nodes documents metastases. If the ovaries are left in the pelvis at the completion of the surgical procedure and microscopic spread to other pelvic tissues is documented, pelvic irradiation can be administered.

Entities:  

Mesh:

Year:  1990        PMID: 2216191

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  3 in total

1.  Early Stage Adenocarcinoma of Cervix with Ovarian Micrometastasis.

Authors:  Pratibha Singh; Neha Mathur; Suyasha Vyas; Puneet Pareekh
Journal:  J Midlife Health       Date:  2017 Oct-Dec

2.  Isolated port site recurrence of node-negative clinical stage IB1 cervical adenocarcinoma.

Authors:  Uma Deshmukh; Molly McAdow; Jonathan Black; Pei Hui; Masoud Azodi
Journal:  Gynecol Oncol Rep       Date:  2017-03-06

Review 3.  Port-Site Metastasis in Gynecological Malignancies.

Authors:  Kelly Benabou; Wafa Khadraoui; Tarek Khader; Pei Hui; Rodrigo Fernandez; Masoud Azodi; Gulden Menderes
Journal:  JSLS       Date:  2021 Jan-Mar       Impact factor: 2.172

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.